Diana Valente

Dr. Diana Valente

Amyris; Catholic University of Porto
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
Sara GranjaSara Granja
Sara Granja
DVDiana Valente
Diana Valente
Odília QueirósOdília Queirós
Odília Queirós
FBFatima Baltazar
Fatima Baltazar

10 February 2023 in Autophagy
Verified
Journal Article
Open access
FPFrancesca Romana Pellegrini
Francesca Romana Pellegrini
SMSara De Martino
Sara De Martino
GFGiulia Fianco
Giulia Fianco
IVIrene Ventura
Irene Ventura
DVDiana Valente
Diana Valente
Francesca DegrassiFrancesca Degrassi
Francesca Degrassi
Macroautophagy/autophagy has been shown to exert a dual role in cancer i.e., promoting cell survival or cell death depending on the cellular context and the cancer stage. Therefore, development of potent autophagy modulators, with a clear mechanistic understanding of their target action, has paramount importance in both mechanistic and clinical studies. In the process of exploring the mechanism of action of a previously identified cytotoxic small molecule (SM15) designed to target microtubules and the interaction domain of microtubules and the kinetochore component NDC80/HEC1, we discovered that the molecule acts as a potent autophagy inhibitor. By using several biochemical and cell biology assays we demonstrated that SM15 blocks basal autophagic flux by inhibiting the fusion of correctly formed autophagosomes with lysosomes. SM15-induced autophagic flux blockage promoted apoptosis-mediated cell death associated with ROS production. Interestingly, autophagic flux blockage, apoptosis induction and ROS production were rescued by genetic or pharmacological inhibition of OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) or by expressing an O-GlcNAcylation-defective mutant of the SNARE fusion complex component SNAP29, pointing to SNAP29 as the molecular target of SM15 in autophagy. Accordingly, SM15 was found to enhance SNAP29 O-GlcNAcylation and, thereby, inhibit the formation of the SNARE fusion complex. In conclusion, these findings identify a new pathway in autophagy connecting O-GlcNAcylated SNAP29 to autophagic flux blockage and autophagosome accumulation, that, in turn, drives ROS production and apoptotic cell death. Consequently, modulation of SNAP29 activity may represent a new opportunity for therapeutic intervention in cancer and other autophagy-associated diseases.

30 June 2013 in Journal of Bioenergetics and Biomembranes
Verified
Journal Article
Closed access
PDF file
DVDiana Valente
Diana Valente
FBFatima Baltazar
Fatima Baltazar
RMRoxana Moreira
Roxana Moreira
Odília QueirósOdília Queirós
Odília Queirós

15 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
DVDiana Valente
Diana Valente
MGMaria Pia Gentileschi
Maria Pia Gentileschi
AGAntonino Guerrisi
Antonino Guerrisi
VBVicente Bruzzaniti
Vicente Bruzzaniti
AMAldo Morrone
Aldo Morrone
AVAlessandra Verdina
Alessandra Verdina
People exposed to ionizing radiation (IR) both for diagnostic and therapeutic purposes is constantly increasing. Since the use of IR involves a risk of harmful effects, such as the DNA DSB induction, an accurate determination of this induced DNA damage and a correct evaluation of the risk–benefit ratio in the clinical field are of key relevance. γH2AX (the phosphorylated form of the histone variant H2AX) is a very early marker of DSBs that can be induced both in physiological conditions, such as in the absence of specific external agents, and by external factors such as smoking, heat, background environmental radiation, and drugs. All these internal and external conditions result in a basal level of γH2AX which must be considered for the correct assessment of the DSBs after IR exposure. In this review we analyze the most common conditions that induce H2AX phosphorylation, including specific exogenous stimuli, cellular states, basic environmental factors, and lifestyles. Moreover, we discuss the most widely used methods for γH2AX determination and describe the principal applications of γH2AX scoring, paying particular attention to clinical studies. This knowledge will help us optimize the use of available methods in order to discern the specific γH2AX following IR-induced DSBs from the basal level of γH2AX in the cells.

17 August 2022 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
Ana OliveiraAna Oliveira
Ana Oliveira
DVDiana Valente
Diana Valente
HMHelena Moreira
Helena Moreira
Manuela PintadoManuela Pintado
Manuela Pintado
PCPatrícia S. Costa
Patrícia S. Costa

26 October 2020 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
FSFrancesca Sardina
Francesca Sardina
APAlessandra Pisciottani
Alessandra Pisciottani
MFManuela Ferrara
Manuela Ferrara
DVDiana Valente
Diana Valente
MCMarialuisa Casella
Marialuisa Casella
CRcinzia rinaldo
cinzia rinaldo
Hereditary Spastic Paraplegia (HSP) is a neurodegenerative disease most commonly caused by autosomal dominant mutations in the SPG4 gene encoding the microtubule-severing protein spastin. We hypothesise that SPG4-HSP is attributable to reduced spastin function because of haploinsufficiency; thus, therapeutic approaches which elevate levels of the wild-type spastin allele may be an effective therapy. However, until now, how spastin levels are regulated is largely unknown. Here, we show that the kinase HIPK2 regulates spastin protein levels in proliferating cells, in differentiated neurons and in vivo. Our work reveals that HIPK2-mediated phosphorylation of spastin at S268 inhibits spastin K48-poly-ubiquitination at K554 and prevents its neddylation-dependent proteasomal degradation. In a spastin RNAi neuronal cell model, overexpression of HIPK2, or inhibition of neddylation, restores spastin levels and rescues neurite defects. Notably, we demonstrate that spastin levels can be restored pharmacologically by inhibiting its neddylation-mediated degradation in neurons derived from a spastin mouse model of HSP and in patient-derived cells, thus revealing novel therapeutic targets for the treatment of SPG4-HSP.